New MS trials result from the American Academy of Neurology (AAN) 2022 Annual Meeting
New data from a phase 3 clinical trial suggests that nearly three of every four participants with primary or secondary progressive MS who were treated with Ocrevus showed no evidence of disease progression after a year of treatment.
Treatment with Kesimpta (ofatumumab) for more than three years revealed no new or unexpected safety findings. The drug continued to slow disability progression and prevent the development of new brain lesions in relapsing MS. These results are from a long-term extension study.
According to 2.5 years of data from a Phase 2 extension study, treatment with Evobrutinib (a BTK inhibitor) safely and effectively reduces the rate of relapses in adults with relapsing MS.
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service, or treatment.